Yogita Ale
Department of Pharmaceutics, Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Dehradun, 248007, Uttarakhand, India

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

Design and development of transferrin conjugated quercetin-loaded nanostructured lipid carrier for cancer therapy Yogita Ale; Vikash Jakhmola; Shivani Kala; Malvika Kandpal
Journal of Applied Pharmaceutical Research Vol. 14 No. 5 (2026)
Publisher : Creative Pharma Assent

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.69857/joapr.v14i5.2149

Abstract

Background: Glioblastoma multiforme is a highly invasive and aggressive brain cancer, with limited therapy options mostly due to the restrictive properties of the blood-brain barrier (BBB). The BBB limits the penetration of most therapeutic agents, leading to inadequate tumor specificity.  The tumor microenvironment exhibits overexpression of transferrin receptors on the BBB endothelial cells, facilitating receptor-mediated drug delivery. Methodology: This study involved the preparation of Quercetin (Que) loaded nanostructured lipid carriers (NLCs) employing the Box-Behnken design (BBD)of experimental methodology. The optimized formulation was subsequently conjugated with transferrin via EDC-mediated covalent conjugation. The attributes of the Que-NLCs and Tf-Que NLCs were validated using particle size, zeta potential, entrapment efficiency, drug loading, in vitro drug release, scanning electron microscopy (SEM), and transmission electron microscopy (TEM). NMR and coupling efficacy validated the conjugation of Tf on the surface of Que-NLCs. Results and Discussion: The in vitro investigation on the U251 cell line revealed that Que-NLCs showed potential anticancer activity with an IC₅₀ value of 20.8 μg/mL, and the optimized Tf-Que-NLCs (Tf/lipid ratio 20:80) exhibited an IC₅₀ value of 17.6 μg/mL. Tf-Que-NLCs showed higher cellular uptake (28.75 1.42%) and better permeability (1.5 times) than the standard drug and Que-NLCs in the BBB model hCMEC/D3 cell line, confirming receptor-mediated drug transport. The apoptosis investigation demonstrated planned cell death mostly via early and late apoptotic pathways, with no necrosis, suggesting a regulated cytotoxic mechanism. Conclusion: The results indicate that Tf-Que-NLCs constitute a promising nanocarrier formulation for the effective treatment of glioblastoma.